Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Current Deferred Revenue (2024 - 2025)

Lipocine (LPCN) has disclosed Current Deferred Revenue for 2 consecutive years, with $320000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Deferred Revenue changed N/A year-over-year to $320000.0, compared with a TTM value of $320000.0 through Sep 2025, changed N/A, and an annual FY2024 reading of $320000.0, changed N/A over the prior year.
  • Current Deferred Revenue was $320000.0 for Q3 2025 at Lipocine, roughly flat from $320000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $320000.0 in Q4 2024 and bottomed at $320000.0 in Q4 2024.